Literature DB >> 11904129

Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression.

Joseph F Cubells1, Lawrence H Price, Barnett S Meyers, George M Anderson, Cyrus P Zabetian, George S Alexopoulos, J Craig Nelson, Gerard Sanacora, Paul Kirwin, Linda Carpenter, Robert T Malison, Joel Gelernter.   

Abstract

BACKGROUND: Plasma activity of dopamine beta-hydroxylase (DbetaH), the enzyme that converts dopamine to norepinephrine, is reportedly lower in patients with unipolar major depression with psychotic features (UDPF) than in those with nonpsychotic unipolar major depression (UD). Plasma DbetaH is under genetic control by the structural locus encoding DbetaH protein, DBH. This study tested the hypothesis that diagnosis-specific allelic variation at DBH accounts for lower plasma DbetaH in UDPF.
METHODS: Plasma DbetaH activity was measured in samples from patients with UDPF (n = 33) and UD (n = 45). Genotypes were determined at several functional DBH polymorphisms, including C-1021T, a single nucleotide polymorphism (SNP) in the proximal 5' region that associates with variation in plasma DbetaH activity.
RESULTS: Mean plasma DbetaH activity was significantly lower in UDPF than in UD. Genotyping at DBH did not reveal genetic associations distinguishing UDPF from UD. A two-way analysis of variance showed significant effects of genotype and diagnostic group but no significant interaction.
CONCLUSIONS: Although the effects of the diagnosis of UDPF, and of DBH allele status, on plasma DbetaH activity were replicated, the lower plasma DbetaH in patients with UDPF was not accounted for by DBH genotype. Several explanations for this result are possible. First, other variants at DBH, or at other loci, could account for the findings. Second, nongenetic factors could account for the differences in plasma DbetaH. In this regard, we hypothesize that abnormal regulation of hypothalamic-pituitary-adrenal function in UDPF lowers expression of DbetaH protein, which could in turn alter the ratio of dopamine and norepinephrine in noradrenergic neurons, thereby promoting development of psychotic symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904129     DOI: 10.1016/s0006-3223(01)01349-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  The DBH -1021 C/T polymorphism is not associated with alcoholism but possibly with patients' exposure to life events.

Authors:  M T M V Freire; M H Hutz; C H D Bau
Journal:  J Neural Transm (Vienna)       Date:  2005-09       Impact factor: 3.575

3.  Polymorphisms in the DBH and DRD2 gene regions and smoking behavior.

Authors:  Maria Teresa M V Freire; Francine Z C Marques; Mara H Hutz; Claiton H D Bau
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-21       Impact factor: 5.270

Review 4.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  The catecholamine biosynthetic enzyme dopamine β-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter.

Authors:  Maja Mustapic; Adam X Maihofer; Manjula Mahata; Yuqing Chen; Dewleen G Baker; Daniel T O'Connor; Caroline M Nievergelt
Journal:  Hum Mol Genet       Date:  2014-06-30       Impact factor: 6.150

6.  Genotype-controlled analysis of serum dopamine β-hydroxylase activity in civilian post-traumatic stress disorder.

Authors:  Yi-lang Tang; Wenbiao Li; Kristina Mercer; Bekh Bradley; Charles F Gillespie; Robert Bonsall; Kerry J Ressler; Joseph F Cubells
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-08-22       Impact factor: 5.067

Review 7.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

8.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

9.  A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders.

Authors:  C Hess; A Reif; A Strobel; A Boreatti-Hümmer; M Heine; K-P Lesch; C P Jacob
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

10.  Association between migraine and a functional polymorphism at the dopamine beta-hydroxylase locus.

Authors:  F Fernandez; N Colson; S Quinlan; J MacMillan; R A Lea; L R Griffiths
Journal:  Neurogenetics       Date:  2009-02-14       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.